Valeant Pharmaceuticals International
Tel: 800-548-5100 or 949-461-6000
About Valeant Pharmaceuticals InternationalValeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
CEO: Joseph C. Papa
CMO: Tage Ramakrishna
CFO: Robert Rosiello
Please click here for clinical trial information.
Please click here for Valeant job opportunities.
953 articles with Valeant Pharmaceuticals International
A former Valeant Pharmaceuticals and a former Philidor Rx Services have been found guilty of using a kickback scheme to defraud the company.
Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl Investors
Kyros Law Offices is alerting investors of Valeant that it is filling legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 16, 2018 at 10:40 a.m. PDT (1:40 p.m. EDT).
Valeant Pharmaceuticals will change its name to Bausch Health Companies Inc. in July of this year. The company will rebrand itself with the highly recognizable name of its subsidiary eye-care company Bausch + Lomb.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Valeant Pharmaceuticals International, Inc. announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, is scheduled to participate at the Goldman Sachs Third Annual Leveraged Finance Conference.
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
Valeant Pharmaceuticals International, Inc. announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection.
Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting
Bausch + Lomb announced that nearly a dozen scientific posters will highlight the results of studies featuring several of the company's current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu from April 29 - May 3, 2018.
Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program
Bausch + Lomb announced today that its ONE by ONE Recycling Program, the first contact lens recycling program of its kind, has recycled nearly 2.5 million used contact lenses, blister packs and top foils since the program launched in November 2016.
Valeant Announces Redemption of $150 Million Aggregate Principal Amount of Its Outstanding 6.375% Senior Unsecured Notes Due 2020
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant, will redeem $150 million aggregate principal amount of its outstanding 6.375% Senior Unsecured Notes due 2020 (the "Notes"), using cash on hand, on May 14, 2018 and issued today an irrevocable notice of redemption for the Notes.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that the Arbitral Tribunal issued a decision (rendered on April 9, 2018) relating to the arbitration between Santarus Inc. and Valeant Pharmaceuticals Ireland (collectively "Valeant"), and Cosmo Technologies Ltd. and Cosmo Technologies III Ltd. (collectively, "Cosmo"), the licensor of certain intellectual property rights in, and supplier of, Valeant's UCERIS® extended release tablets.
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology
DUOBRII Demonstrated Significant Superiority Over Vehicle As Early As Two Weeks
Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020
"Addressing our debt remains a priority for us as we continue to transform Valeant," said Joseph C. Papa, chairman and CEO, Valeant.
"2017 was a year of strong progress for Valeant as we delivered organic growth2 across nearly 75 percent of the Company while significantly reducing our debt and investing in our Bausch + Lomb, Salix and Ortho Dermatologics businesses," said Joseph C. Papa, chairman and CEO, Valeant.
Patients are discovering that Teva’s generic isn’t really that much cheaper than Valeant Pharmaceutical’s branded drug to treat Wilson's Disease.
Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update.
When the debt is repaid next week, Valeant will have reduced its debt by more than $6.7 billion since the end of the first quarter of 2016..
Valeant's CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges.
1/8/2018Just before ringing in the new year, Valeant has managed to resolve another crisis.